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ABSTRACT
Introduction: Diazoxide is the first-line treatment used to manage infants and children with hypoglycemia
secondary to hyperinsulinemic hypoglycemia (HH), after initial stabilization of blood glucose. Recent
changes in Pediatric Endocrine Society guidelines regarding definition of, and screening for hypoglycemia
in the neonate led to an increase in the number of infants treated with diazoxide.
Previous studies have noted various side effects of diazoxide. With the increased use of this drug in
neonates, our aim is to further evaluate these side effects.
Methods: We performed a retrospective case control analysis of all neonates admitted to a tertiary care
center in New Jersey who were treated with diazoxide for hypoglycemia after a confirmed diagnosis of HH
between 1/1/2015 and 9/1/2019. All subjects were younger than 6 months of age at treatment initiation
with diazoxide. We collected data regarding general patient characteristics, diuretic dosing, findings on
echocardiogram, blood counts, episodes of emesis, and quantity of feeds at time points before and after
diazoxide initiation.
Results: A total of 25 infants (64% males) met inclusion criteria and were included in the analysis. Based on
echocardiogram results, one baby (4%) had pulmonary hypertension (PHTN) prior to initiation of diazoxide,
and 20% after, with 5 cases (20%) of reopening of the ductus arteriosus (DA). Nine patients (36%) required
a diuretic dose increase after diazoxide initiation. There was increased feeding intolerance with increased
number of emesis events after diazoxide initiation (p=0.006). A week after initiation of diazoxide, there was
no improvement in the percent of total oral intake as would typically be expected.
Conclusion: New onset PHTN and re-opening of the DA were associated with initiation of diazoxide
treatment. Significant increase in emesis after diazoxide initiation suggests that infants may be
experiencing feeding difficulties associated with this medication. Larger studies are needed to further
evaluate the extent and frequencies of these side effects.
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INTRODUCTION

Hyperinsulinism is the most common cause of persistent or recurrent hypoglycemia in infants1.
Appropriately treating neonates with hypoglycemia is important in reducing the risk of developing
seizures, brain damage, and long-term developmental delay2. In hyperinsulinemic hypoglycemia (HH), an
inappropriately high level of insulin has an inhibitory effect on lipolysis and ketogenesis3. Suppressing
ketone body formation limits the brain’s backup source of fuel during periods of hypoglycemia, making
infants with HH especially vulnerable to developing neurologic sequelae of hypoglycemia3.
Diazoxide, in combination with the diuretic chlorothiazide, is currently the first-line treatment used to
manage those infants and children with hypoglycemia secondary to hyperinsulinism, after initial
stabilization of blood glucose3 . There is a lack of consensus regarding a specific blood glucose value that
defines hypoglycemia in neonates4. Both the American Academy of Pediatrics and the Pediatric Endocrine
Society published conflicting guidelines regarding definition of and screening for hypoglycemia in the
neonate in 2011 and 2015, respectively4 . Gray et al report that from 1997 to 2016, the percentage of infants
treated with diazoxide and the percentage of infants diagnosed with hypoglycemia increased significantly,
which may have been attributable to the publication of these guidelines5. This increased use of diazoxide in
neonates has prompted heightened concern regarding the side effects of diazoxide in this specific
population.
Diazoxide inhibits insulin secretion by acting as a β-cell KAT P channel opener, which hyperpolarizes the
membrane and prevents insulin secretion6. Due to its mechanism, diazoxide can lead to an increase in
sodium retention and subsequent decrease in water clearance6. Circulatory complications such as fluid
retention and, in severe cases pulmonary hypertension (PHTN), have been reported following treatment with
diazoxide7. Both Herrera and Yoshida reported circulatory dysfunction, defined as edema, oliguria and/or
reopening of the ductus arteriosus (DA), or PHTN in infants treated with diazoxide, with younger
gestational age at birth and higher maximum doses of diazoxide as main risk factors7,8. Several other side
effects have been associated with diazoxide therapy. It can cause blood dyscrasias, as demonstrated in a
number of studies and case reports7,9,10.
In addition to circulatory complications and blood dyscrasias, feeding difficulties have been observed as a
possible side effect of diazoxide therapy in neonates. Hu et al reported that children were seen to have
transient gastrointestinal (GI) reactions11. Additional data regarding gastro-intestinal (GI) disturbances and
feeding difficulty in neonates receiving diazoxide is lacking and was therefore a focus of this study.
This study reports the incidence of various side effects in neonates treated with diazoxide for
hypoglycemia after a diagnosis of HH. This article pays special attention to side effects within the realm of
circulatory compromise, blood cell dyscrasias and feeding difficulties. This study adds to existing
literature on these particular side effects and expands on them, particularly the GI side effects.
https://rdw.rowan.edu/crjcsm/vol3/iss1/5
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MATERIALS AND METHODS

This was an IRB-approved retrospective case series of all neonates admitted to a tertiary care hospital in
New Jersey who were treated with diazoxide for hypoglycemia after a confirmed diagnosis of HH between
January 1, 2015 and September 1, 2019. To be included in the study, subjects had to be younger than six
months of age at treatment initiation with diazoxide for hypoglycemia. Infants were excluded if they were
older than six months of age at treatment initiation, or if they were not treated with diazoxide for
hypoglycemia. Information was gathered on general patient characteristics including gender, birth weight,
gestational age at birth, and age and weight at treatment initiation with diazoxide. Data regarding diazoxide
dosing, duration of therapy, concurrent treatment with diuretics and diuretic dosing was also collected using
electronic medical records (EPIC).
Echocardiogram was performed before and after treatment initiation of diazoxide for each subject and was
read by a pediatric cardiologists. PHTN was defined by a clinician diagnosis in the echocardiogram report,
with supportive findings including bidirectional or right-to-left patent DA or intracardiac shunt, and/or
flattening of the ventricular septum during systole.
Additional data points that were collected included platelet, neutrophil and lymphocyte values. To obtain
these values, we evaluated closest complete blood count (CBC) drawn prior to the date of diazoxide
initiation as the “before,” and the CBC drawn within a week post diazoxide initiation as the “after.” We
also obtained the total number of emesis episodes for the three days before and after diazoxide initiation.
To evaluate feeding tolerance, we recorded quantity and percent of oral (PO) intake and intake via
nasogastric/orogastric (NG/OG) tube 24 hours prior, 24 hours after, and 1 week after initiation of
treatment. For all variables with time points relating to treatment initiation, the treatment initiation time
point was considered as 7 AM on the morning of the day the medication was started. The time periods
chosen for analysis were determined based on standard time periods evaluated for the same variables in
other similar studies as well as clinical experience.
Descriptive analysis was performed with means (standard deviations), medians (ranges), percentages, or
frequencies reported as appropriate. To compare continuous or discrete measures before and after the
administration of diazoxide, we utilized a paired t-test or repeated measures ANOVA. For categorical
measures, we utilized the Chi Test or McNemar test. Statistical significance was considered for p<0.05.

RESULTS

A total of 25 patients (64% males) were identified as meeting inclusion criteria, with a mean gestational
age of 35.65 weeks (±3.99), and mean birthweight of 2112 grams (±954). Diazoxide was initiated at
mean 13.8 postnatal days (+/-12.41) and mean weight of 2376 grams (+/-827.71). Cohort characteristics
Published by Rowan Digital Works, 2021
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are included in Table 1.
Average length of treatment was 19.6 (±15.9) days. The mean initial dose of diazoxide was 10.9 (±2.2)
mg/kg/day. The mean maximum dose of diazoxide was 12.1 (±2.7) mg/kg/day.
Circulatory Complications
Before diazoxide initiation, one patient (4%) had PHTN documented on their echocardiogram report, versus
5 cases (20%) of PHTN present after diazoxide initiation (p=0.13). Consistent with current guidelines, all
but one patient was started on chlorthiazide therapy at time of diazoxide initiation (the remaining patient
was started on furosemide). Nine patients (36%) required an increase in the dose of their diuretic after
diazoxide initiation, with a mean maximum dose of chlorthiazide of 18.28 (median 15; 10-40 , ±9.7)
mg/kg/day. There were 5 cases (20%) of reopening of the DA, defined as a patent DA that was reported on
the echocardiogram performed after treatment initiation, that was not present on the echocardiogram prior to
diazoxide initiation.
Blood Cell Dyscrasias
We analyzed blood cell counts from subjects who had a CBC with differential completed within a week
before diazoxide initiation (n=15). The mean platelet, leukocyte, and neutrophil counts before and after
diazoxide initiation are shown in Table 2.
Feeding Difficulties
The average number of episodes of emesis in the three days after diazoxide initiation was significantly
higher than three days before (1.24 +/- 1.5 and 0.28 +/- 0.3 respectively, p=0.006). We collected PO intake
quantity and percent compared to intake via NG/OG tube for the 24 hours prior to, 24 hours after, and 1
week after diazoxide initiation (Table 3 , Figure 1). These results did not reach statistical significance.

DISCUSSION

Diazoxide use in neonates has been increasing over the past 40 years and remains the first-line treatment used to
manage infants and children with hypoglycemia secondary to HH5. Concern regarding these side effects was
heightened when in 2015 the FDA issued a drug safety communication warning of the association between PHTN and
diazoxide use in neonates12. In addition to circulatory complications, such as PHTN and re-opening of the DA, various
other side effects have been reported, includingneutropenia, thrombocytopenia, and transient GI side effects.
PHTN remains the most concerning complication of diazoxide use in neonates, and clinically may lead to heart failure,
increased oxygen requirement, ventilator requirement, or need for increased diuretic dosing5. Our study found a 20%
incidence of PHTN after diazoxide initiation, which is higher than other recent studies5,7,10. Other investigators report
https://rdw.rowan.edu/crjcsm/vol3/iss1/5
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lower rates of PHTN after diazoxide exposure (2.0%, 2.4% and 4.8%, respectively)5,7,10. In these studies, infants that
developed PHTN were more likely to be premature and have a risk factor for PHTN at the time of diazoxide initiation.
Several additional published case studies demonstrate cases of cardiac failure and PHTN in infants treated with
diazoxide13–15. Although we report a high incidence of PHTN after diazoxide initiation, clinically none of our subjects
developed overt heart failure, and the PHTN eventually resolved with continued diuretic therapy. The severity of PHTN
in our patients never necessitated cessation of diazoxide therapy. It is possible that our patients had more of the
underlying factors that increased the risk of developing PHTN, compared to the other studies.
We also report a 20% incidence of re-opening of the DA after initiation with diazoxide therapy. Demirel et
al report a case of an infant treated with diazoxide who developed both PHTN and reopening of the DA16,
and Yoshida et al reported 3 cases (3.8%) of reopening of the DA8. In our study, reopening of the DA was
not exclusive to patients who experienced PHTN after diazoxide initiation, suggesting that these events can
occur exclusive of one another, despite a likely similar underlying mechanism of fluid retention. The
clinical significance of this finding is unclear and necessitates further studies. However, it supports the
evidence that diazoxide leads to circulatory alterations in neonates.
Previous studies have reported blood cell dyscrasias in neonates after diazoxide therapy including
thrombocytopenia and neutropenia. Yildizdas et al describe a four-month-old infant who developed PHTN,
heart failure and neutropenia during diazoxide therapy, which resolved once the drug was withdrawn9.
Herrera et al. report that among 295 children with HH treated with diazoxide, 15.6 % developed
neutropenia and 4.7% developed thrombocytopenia7. Thornton et al reported that among 165 infants treated
with diazoxide, 8 (4.8%) experienced neutropenia10. Although not statistically significant, we observed a
slight thrombocytosis a week following diazoxide initiation compared to prior. We observed no significant
change in the total leukocyte count or absolute neutrophil count after diazoxide initiation. Although the
numbers of patients evaluated in our study is smaller, based on our data special monitoring for blood cell
dyscrasias may not be necessary while on diazoxide therapy, unless indicated for other medical reasons.
Hu et al reported that out of 44 patients, 12 suffered transient GI reactions after treatment with diazoxide11
, and no other studies have looked further into the incidence of such reactions. A study by Keyes et al of 24
neonates in the intensive care unit who received diazoxide for HH showed that 20% of the subjects
developed necrotizing enterocolitis (NEC) after treatment initiation with diazoxide, which is above the
baseline incidence of NEC (1% for all infants and 6% for all very low birth weight infants)17 . None of the
subjects in our study developed NEC, however we did observe a significant increase in the number of
emesis events during the three days after diazoxide initiation compared to the three days before. This is
important in the clinical setting, as even seemingly small amounts of emesis can affect growth and disturb
fluid and electrolyte status in neonates. Typically, an improvement in PO intake in neonates learning to
take oral feeds would be expected over time, with continued improvement in clinical status. However, we
found a mild decrease in the percent of total PO intake (versus NG/OG tube) the week after diazoxide
Published by Rowan Digital Works, 2021
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initiation compared to the 24 hours before therapy was initiated. Due to lack of control, the clinical
significance of this decrease could not by appreciated. However, the trend of our data suggests that
diazoxide treatment may lead to feeding difficulties and clinicians may need to alter feeding route and/or
amount in neonates treated with diazoxide to avoid emesis and other GI side effects. This finding is also
very important when diazoxide is initiated in outpatient setting, as infants may have decreased PO intake
that goes unrecognized by the caregiver, and may lead to dehydration and failure to thrive. Larger studies
are needed to further characterize GI side effects and feeding disturbances in neonates treated with
diazoxide.
There are several limitations to our study. Our sample size was small, especially when analyzing blood cell
counts, as we had to exclude patients who did not have a CBC with differential done both before and after
diazoxide initiation. Another limitation is that due to the study design, we are only able to report association,
not cause and effect. Lastly, as with any chart review study, there is potential error at the time of clinical
documentation by medical staff. Data points such as emesis are reliant on nursing staff accurately recording
such events, and data points like echocardiogram results depend on the personnel interpreting the study.

CONCLUSIONS

Our data supports existing evidence that cardiovascular complications, such as new onset PHTN and
re-opening of the DA are associated with initiation of diazoxide treatment. Clinicians should continue to
follow current guidelines regarding diuretic treatment during diazoxide therapy and be vigilant for signs of
fluid overload and its sequelae. We did not observe any significant side effects regarding blood cell
dyscrasias in our sample, which may help decrease blood tests that are needed in monitoring of patients on
diazoxide. Lastly, there were notable GI complications seen after diazoxide initiation in our sample,
including a lack of improvement in PO intake and a significant increase in emesis events. Clinicians should
monitor for signs of GI upset and feeding difficulty and adjust feeding amount and route
accordingly. As diazoxide appears to be used more liberally among neonates, larger studies are needed to
further evaluate the extent and severity of side effects seen with this medication.
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Table 1 Cohort Characteristics (n=25)

Characteristic

Data

Gender, n (%) Male

16 (64)

Gestational age at birth, weeks Mean (SD)

35.65 (3.99)

Birthweight, grams Mean (SD)

2112.12 (954.17)

Postnatal age at diazoxide initiation, days Mean (SD)

13.76 (12.41)

Gestational age at diazoxide initiation, days Mean (SD)

37.61 (2.88)

Weight at diazoxide initiation, grams Mean (SD)

2375.76 (827.71)
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Table 2 Select blood cell counts before and after diazoxide initiation

Prior to diazoxide

After diazoxide

p

Platelet count (mean +/- SD, 103 cells/mL)

149.13 +/- 100.5

212.93 +/- 108.2

0.127

Leukocyte count (mean +/- SD, 103 cells/mL)

10.89 +/- 3.0

10.34 +/- 4.3

0.612

Neutrophil count (mean +/- SD, 103 cells/mL)

4.99 +/- 2.8

3.93 +/- 2.4

0.191

https://rdw.rowan.edu/crjcsm/vol3/iss1/5
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Table 3 Intake orally and via NG/OG tube prior to and after diazoxide initiation

Oral Intake (mean +/- SD,

24 hours prior to

24 hours after

1 week after

diazoxide

diazoxide

diazoxide

61.67 +/- 60.6

80.54 +/- 74.3

72.62 +/- 67.4

36.10 +/- 48.3

40.10 +/- 47.6

58.50 +/- 50.6

56.14 +/- 44.2

55.92 +/- 44.9

52.30 +/- 41.5

mL/kg/day)
NG/OG tube Intake (mean +/- SD,
mL/kg/day)
% oral intake of total (mean +/SD, %)
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Figure 1 Oral Intake vs. Intake via NG/OG Tube

https://rdw.rowan.edu/crjcsm/vol3/iss1/5
DOI: 10.31986issn.2578.3343_vol3iss1.4

146

Begun MD et al.: Adverse Effects Associated with Diazoxide Use in Neonates

REFERENCES

1. Aynsley-Green A, Hussain K, Hall J, et al. Practical management of hyperinsulinism in infancy.
Archives of Disease in Childhood - Fetal and Neonatal Edition. 2000;82:98-107.
2. Steinkrauss L, Lipman T H, Hendell C D, Gerdes M, Thornton P S, Stanley C A. Effects of
Hypoglycemia on Developmental Outcome in Children with Congenital Hyperinsulinism. Journal of
Pediatric Nursing. 2005;20:109-118.
3. Demirbilek H, Hussain K. Congenital Hyperinsulinism: Diagnosis and Treatment Update. Journal of
Clinical Research in Pediatric Endocrinology. 2017;9:69-87.
4. Thompson-Branch A, Havranek T, Hypoglycemia . Pediatrics in Review. 2017;38:147-157.
5. Gray K D, Dudash K, Escobar C, Freel C, Harrison T, Mcmillan C. Prevalence and safety of diazoxide in
the neonatal intensive care unit. Journal of Perinatology. 2018;38:1496-1502.
6. Sweet C B, Grayson S, Polak M. Management Strategies for Neonatal Hypoglycemia. The Journal of
Pediatric Pharmacology and Therapeutics: JPPT. 2013;18(3):199-208.
7. Herrera A, Vajravelu M E, Givler S, et al. Prevalence of Adverse Events in Children With Congenital
Hyperinsulinism Treated with Diazoxide. The Journal of Clinical Endocrinology & Metabolism.
2018;103(12):4365-72.
8. Yoshida K, Kawai M, Marumo C, et al. High prevalence of severe circulatory complications with
diazoxide in premature infants. Neonatology. 2013;105(3):166-171.
9. Yildizdas D, Erdem S, Küçükosmanoǧlu O, Yilmaz M, Yüksel B. Pulmonary hypertension, heart
failure and neutropenia due to diazoxide therapy. Advances in Therapy. 2008;25:515-515.
10. Thornton P, Truong L, Reynolds C, Hamby T, Nedrelow J. Rate of Serious Adverse Events Associated with
Diazoxide Treatment of Patients with Hyperinsulinism. Hormone Research in Pediatrics. 2019;91:25-32.
11. Hu S, Xu Z, Yan J, et al. The treatment effect of diazoxide on 44 patients with congenital
hyperinsulinism. Journal of Pediatric Endocrinology and Metabolism: JPEM. 2012;25:1119-1141.
12. Food 12.US, administration Drug. FDA warns about a serious lung condition in infants and newborns
treated with Proglycem (diazoxide). 2018.

Published by Rowan Digital Works, 2021

147

Cooper Rowan Medical Journal, Vol. 3, Iss. 1 [2021], Art. 5

13. Mcgraw M E, Price D A. Complications of diazoxide in the treatment of nesidioblastosis. Archives of
Disease in Childhood. 1985;60(1):62-64.
14. Timlin M R, Black A B, Delaney H M, Matos R I, Percival C S. Development of Pulmonary
Hypertension During Treatment with Diazoxide: A Case Series and Literature Review. Pediatric
Cardiology. 2017;38(6):1247-1250.
15. Nebesio T D, Hoover W C, Caldwell R L, Nitu M E, Eugster E A. Development of pulmonary
hypertension in an infant treated with diazoxide. Journal of Pediatric Endocrinology and Metabolism:
JPEM. 2007;20(8):939-983.
16. Demirel F, Unal S, Cetin I I, Esen I, Arasli A. Pulmonary hypertension and reopening of the ductus
arteirosus in an infant treated with diazoxide. Journal of Pediatric Endocrinology and Metabolism: JPEM.
2011;24(7-8):603-605.
17. Keyes M L, Healy H, Sparger K A, et al. Hyperinsulinemic Hypoglycemia Treated With Diazoxide.
Pediatrics. 2021;147(2):20193202-20193202.

https://rdw.rowan.edu/crjcsm/vol3/iss1/5
DOI: 10.31986issn.2578.3343_vol3iss1.4

148

